Pilot Study of rhBMP-2/BCP in Patients With Spinal Degeneration With Instability Requiring Surgical Fusion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01495234
Recruitment Status : Completed
First Posted : December 19, 2011
Last Update Posted : August 2, 2013
Information provided by (Responsible Party):
Medtronic Spinal and Biologics

Brief Summary:
This study is designed to generate data relating to patient safety, bone generating activity associated with the use of the rhBMP-2/BCP device as compared to autograft and to evaluate the feasibility of conducting a larger clinical trial in a patient population requiring spinal fusion.

Condition or disease Intervention/treatment Phase
Degenerative Disc Disease Device: rhBMP-2/BCP device Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Investigation of Recombinant Human Bone Morphogenetic Protein- 2/Biphasic Calcium Phosphate in Patients With Spinal Degeneration With Instability Requiring Surgical Fusion
Study Start Date : October 1996
Actual Primary Completion Date : June 2001
Actual Study Completion Date : June 2001

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Cohort 1
Each patient will receive 15mg of rhBMP-2 in rhBMP-2/BCP device and implant unilaterally during a posterolateral spinal fusion procedure. The contralateral side was fused using standard fusion techniques with autograft bone.
Device: rhBMP-2/BCP device
The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
Other Name: Recombinant human bone morphogenetic protein-2
Experimental: Cohort 2
Each patient will receive 20mg of rhBMP-2 in rhBMP-2/BCP device and implant bilaterally.
Device: rhBMP-2/BCP device
The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
Other Name: recombinant human Bone Morphogenetic Protein-2

Primary Outcome Measures :
  1. Fusion Status [ Time Frame: 12 month ]

    Fusion will be met all of the following criteria:

    1. Evidence of bridging trabecular bone;
    2. Angular motion < 5°;
    3. Translational motion <= 3mm;
    4. No radiolucent lines spanning the entire fusion mass.

Secondary Outcome Measures :
  1. Oswestry Low Back Pain Disability Questionnaire Status [ Time Frame: 12 month ]
  2. Neuro/Functional Status [ Time Frame: 12 month ]
    A neurological functional questionnaire will be completed by patients prior to surgery and postoperative, including three questions pertaining to pain (severity of pain, location of pain, and leg pain side), and four questions associated with functional activities (recreational activity level, putting on shoes and socks, squatting, occupation activity level). Success will be based on a maintenance or improvement from the preoperative condition for the functional components, except that severity of pain success will be based on an improvement of at least one point on the five point scale.

  3. Neurological Status [ Time Frame: 12 month ]
    A scale will be used to measure neurological status. This scale focuses on reflexes, sensory, motor function, and the degree of straight leg raise reproducing pain. All of these elements are combined to give an overall score. Success will be based on a maintenance or improvement in all categories from the preoperative condition.

  4. General Health Status (SF-36) [ Time Frame: 12 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject has radiographically documented spinal degeneration with instability as documented by the presence of translation >= 4mm or angulation >= 5°.
  • Subject has intractable back pain which does not respond to conservative treatment and in the investigator's opinion, requires surgical spinal fusion.
  • Subject's pain is predominantly associated with the back.
  • Subject has only one level involvement at L3-L4, L4-L5, or L5-S1.
  • Subject is 18 years of age or greater at the time consent is given to participate in the study.
  • Subject is willing to comply with the study plan and sign the informed consent.
  • Subject is male or a non-pregnant, non-nursing female. All females of child-bearing age must agree to use adequate contraception for a period of no less than 16 weeks following surgery.

Exclusion Criteria:

  • Subject has primary spinal diagnosis of a disorder other than spinal degeneration with instability at the involved surgical level.
  • Subject has spinal stenosis or condition which requires a full laminectomy procedure.
  • Subject has had a previous fusion, discectomy or laminectomy procedure at L3-L4, L4-L5 or L5-S1.
  • Subject has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., steroids, methotrexate) or has a condition which requires postoperative medications that interfere with fusion (e.g., steroids, nonsteroidal antiinflammatory drugs, or methotrexate).
  • Subject has overt or active infection near the operative spinal region.
  • Subject has active systemic infection.
  • Subject has history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
  • Subject's history includes hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins).
  • Subject has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation.
  • The subject requires electrical bone growth stimulation, allograft, or bone substitute as part of treatment.
  • Subject has history of endocrine or metabolic disorder known to affect osteogenesis (e.g. Paget's disease, renal osteodystrophy, Ehlers Danlos syndrome, or osteogenesis imperfecta).
  • Subject has a known diagnosis of diabetes which requires treatment with medication.
  • Subject has received previous radiation therapy at the site to be fused.
  • Subject is unwilling to return for required follow-up visits.
  • Subject is a prisoner.
  • Subject has insufficient bone mass which precludes surgery (e.g., severe osteopenia or osteoporosis).

Responsible Party: Medtronic Spinal and Biologics Identifier: NCT01495234     History of Changes
Other Study ID Numbers: DOC#1187b BCP -Mexico
First Posted: December 19, 2011    Key Record Dates
Last Update Posted: August 2, 2013
Last Verified: December 2011

Keywords provided by Medtronic Spinal and Biologics:
Spinal degeneration

Additional relevant MeSH terms:
Intervertebral Disc Degeneration
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases